{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:19:11Z","timestamp":1790302751587,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T00:00:00Z","timestamp":1629504000000},"content-version":"am","delay-in-days":385,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-11\u201310753"],"award-info":[{"award-number":["W81XWH-11\u201310753"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR000040"],"award-info":[{"award-number":["UL1TR000040"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.nmd.2020.07.007","type":"journal-article","created":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T10:59:21Z","timestamp":1595069961000},"page":"693-700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Lack of effect on ambulation of dalfampridine-ER (4-AP) treatment in adult SMA patients"],"prefix":"10.1016","volume":"30","author":[{"given":"Claudia A.","family":"Chiriboga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"LaMarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally Dunaway","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis H.","family":"Weimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nmd.2020.07.007_bib0001","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.nmd.2020.07.007_bib0002","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.nmd.2020.07.007_bib0003","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0960-8966(97)00459-8","article-title":"Spinal muscular atrophy\u2013clinical and genetic correlations","volume":"7","author":"Zerres","year":"1997","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"10.1016\/j.nmd.2020.07.007_bib0004","doi-asserted-by":"crossref","first-page":"e12140","DOI":"10.1371\/journal.pone.0012140","article-title":"SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of l-carnitine and valproic acid in spinal muscular atrophy","volume":"5","author":"Swoboda","year":"2010","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.nmd.2020.07.007_bib0005","doi-asserted-by":"crossref","first-page":"e21296","DOI":"10.1371\/journal.pone.0021296","article-title":"SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of l-carnitine and valproic acid in ambulatory children with spinal muscular atrophy","volume":"6","author":"Kissel","year":"2011","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.nmd.2020.07.007_bib0006","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/01.wnl.0000249142.82285.d6","article-title":"Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy","volume":"68","author":"Mercuri","year":"2007","journal-title":"Neurology"},{"issue":"24","key":"10.1016\/j.nmd.2020.07.007_bib0007","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1212\/WNL.0b013e3182020332","article-title":"Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy","volume":"75","author":"Chen","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.nmd.2020.07.007_bib0008","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.pharmthera.2005.10.006","article-title":"Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment","volume":"111","author":"Judge","year":"2006","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.nmd.2020.07.007_bib0009","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0022-3565(25)31092-X","article-title":"Effects of 4-aminopyridine at the frog neuromuscular junction","volume":"203","author":"Molgo","year":"1977","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nmd.2020.07.007_bib0010","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1113\/jphysiol.1981.sp013666","article-title":"The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres","volume":"313","author":"Bostock","year":"1981","journal-title":"J Physiol"},{"issue":"11","key":"10.1016\/j.nmd.2020.07.007_bib0011","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1523\/JNEUROSCI.17-11-04500.1997","article-title":"Effects of 4-aminopyridine on muscle and motor unit force in canine motor neuron disease","volume":"17","author":"Pinter","year":"1997","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.nmd.2020.07.007_bib0012","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cell.2012.09.011","article-title":"SMN is required for sensory-motor circuit function in drosophila","volume":"151","author":"Imlach","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.nmd.2020.07.007_bib0013","series-title":"Proceedings of the 23rd SMA Research Meeting","article-title":"Chronic Increase in Neuronal Activity by 4-Aminopyridine Improves Sensory Motor Dysfunction in a Mouse Model of SMA","author":"Simon","year":"2019"},{"issue":"8","key":"10.1016\/j.nmd.2020.07.007_bib0014","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1089\/089771501316919120","article-title":"Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury: a double-blinded, placebo-controlled crossover trial","volume":"18","author":"Wolfe","year":"2001","journal-title":"J Neurotrauma"},{"issue":"1","key":"10.1016\/j.nmd.2020.07.007_bib0015","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0022-510X(98)00143-9","article-title":"The effects of 4-aminopyridine on motor evoked potentials in multiple sclerosis","volume":"159","author":"Fujihara","year":"1998","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1016\/j.nmd.2020.07.007_bib0016","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/0022-510X(93)90329-W","article-title":"4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study","volume":"116","author":"van Diemen","year":"1993","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1016\/j.nmd.2020.07.007_bib0017","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.53.4.743","article-title":"Quantitative assessment of motor fatigue and strength in MS","volume":"53","author":"Schwid","year":"1999","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.nmd.2020.07.007_bib0018","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.44.6.1054","article-title":"The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial","volume":"44","author":"Bever","year":"1994","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.nmd.2020.07.007_bib0019","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.wnl.0000326213.89576.0e","article-title":"Dose comparison trial of sustained-release fampridine in multiple sclerosis","volume":"71","author":"Goodman","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2020.07.007_bib0020","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.nmd.2020.07.007_bib0021","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.neuron.2010.12.032","article-title":"Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy","volume":"69","author":"Mentis","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.nmd.2020.07.007_bib0022","doi-asserted-by":"crossref","DOI":"10.1038\/nn.4561","article-title":"Reduced sensory synaptic excitation impairs motor neuron function via Kv2.1 in spinal muscular atrophy","volume":"20","author":"Fletcher EV","year":"2017","journal-title":"Nat Neurosci"},{"issue":"3","key":"10.1016\/j.nmd.2020.07.007_bib0023","first-page":"268","article-title":"The hoffmann reflex: methodologic considerations and applications for use in sports medicine and athletic training research","volume":"39","author":"Palmieri","year":"2004","journal-title":"J Athl Train"},{"issue":"18","key":"10.1016\/j.nmd.2020.07.007_bib0024","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","article-title":"Prospective cohort study of spinal muscular atrophy types 2 and 3","volume":"79","author":"Kaufmann","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2020.07.007_bib0025","unstructured":"Fadem S.Z.p. Cystatin C Calculator [Available from:http:\/\/touchcalc.com\/calculators\/cystatin."},{"issue":"5","key":"10.1016\/j.nmd.2020.07.007_bib0026","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/mus.25120","article-title":"Six-minute walk test is reliable and valid in spinal muscular atrophy","volume":"54","author":"Dunaway Young","year":"2016","journal-title":"Muscle Nerve"},{"issue":"10","key":"10.1016\/j.nmd.2020.07.007_bib0027","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1212\/WNL.0b013e3181d3e308","article-title":"Six-minute walk test demonstrates motor fatigue in spinal muscular atrophy","volume":"74","author":"Montes","year":"2010","journal-title":"Neurology"},{"issue":"9\u201310","key":"10.1016\/j.nmd.2020.07.007_bib0028","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","article-title":"An expanded version of the hammersmith functional motor scale for SMA II and III patients","volume":"17","author":"O'Hagen J","year":"2007","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"10.1016\/j.nmd.2020.07.007_bib0029","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.nmd.2020.07.007_bib0030","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2020.07.007_bib0031","series-title":"Medical research council: aids to the investigation of peripheral nerve injuries","year":"1943"},{"key":"10.1016\/j.nmd.2020.07.007_bib0032","series-title":"Electromyography and neuromuscular disorders: clinical and electrophysiologic correlation","year":"2005"},{"issue":"3","key":"10.1016\/j.nmd.2020.07.007_bib0033","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/mus.10050","article-title":"Motor unit number estimation in infants and children with spinal muscular atrophy","volume":"25","author":"Bromberg","year":"2002","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.nmd.2020.07.007_bib0034","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/mus.880160404","article-title":"The estimated numbers and relative sizes of thenar motor units as selected by multiple point stimulation in young and older adults","volume":"16","author":"Doherty","year":"1993","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.nmd.2020.07.007_bib0035","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00421-002-0577-5","article-title":"Considerations for use of the Hoffmann reflex in exercise studies","volume":"86","author":"Zehr","year":"2002","journal-title":"Eur J Appl Physiol"},{"issue":"2","key":"10.1016\/j.nmd.2020.07.007_bib0036","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0165-0270(97)02250-4","article-title":"Neurophysiological methods for studies of the motor system in freely moving human subjects","volume":"74","author":"Capaday","year":"1997","journal-title":"J Neurosci Methods"},{"issue":"10","key":"10.1016\/j.nmd.2020.07.007_bib0037","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","article-title":"The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus","volume":"46","author":"Krupp","year":"1989","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.nmd.2020.07.007_bib0038","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s11136-013-0565-8","article-title":"Fatigue in patients with spinal muscular atrophy type II and congenital myopathies: evaluation of the fatigue severity scale","volume":"23","author":"Werlauff U","year":"2014","journal-title":"Qual Life Res"},{"issue":"9","key":"10.1016\/j.nmd.2020.07.007_bib0039","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1007\/s00415-008-0929-0","article-title":"A natural history study of late onset spinal muscular atrophy types 3b and 4","volume":"255","author":"Piepers","year":"2008","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.nmd.2020.07.007_bib0040","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/16501970510030156","article-title":"Physical complaints in ageing persons with spinal muscular atrophy","volume":"37","author":"de Groot","year":"2005","journal-title":"J Rehabil Med"},{"issue":"2","key":"10.1016\/j.nmd.2020.07.007_bib0041","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/mus.24527","article-title":"Training improves oxidative capacity, but not function, in spinal muscular atrophy type III","volume":"52","author":"Madsen","year":"2015","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.nmd.2020.07.007_bib0042","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.21838","article-title":"Compound muscle action potential and motor function in children with spinal muscular atrophy","volume":"42","author":"Lewelt","year":"2010","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.nmd.2020.07.007_bib0043","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2020.07.007_bib0044","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Efficacy and safety of nusinersen versus sham control in infantile-onset spinal muscular atrophy\u201d nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel RS","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2020.07.007_bib0045","unstructured":"FDA. U.S. Department of Health and Human Services. Center for drug evaluation and research. Application number: 209531Orig1s000. Medical Reviews. 2016[Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/209531Orig1s000MedR.pdf."},{"issue":"4","key":"10.1016\/j.nmd.2020.07.007_bib0046","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/head.12323","article-title":"G. D. Ion channels and migraine","volume":"54","author":"Yan","year":"2014","journal-title":"Headache"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096089662030167X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096089662030167X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:09:42Z","timestamp":1760774982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096089662030167X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S096089662030167X"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2020.07.007","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lack of effect on ambulation of dalfampridine-ER (4-AP) treatment in adult SMA patients","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2020.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}